Super models - PharmaTimes
2024年10月24日 · The impact of AI/data-driven drug discovery is evolving rapidly in life sciences. Harnessing the beneficial potential of this technology, however, requires its optimal integration into R&D says Biorelate’s Dr Ben Sidders.
Chosen path - PharmaTimes
2024年10月24日 · The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval of lecanemab. This particular therapy is a monoclonal antibody treatment for use among patient populations with mild cognitive impairment or mild stages of dementia brought on by Alzheimer’s Disease (AD).
AI, captain? - PharmaTimes
2024年8月9日 · EU AI Act – challenges and opportunities for pharmaceuticals. The EU AI Act intends to regulate artificial intelligence (AI) technology in the European Union with AI systems required to meet strict standards for transparency, accountability and human supervision.
A new dawn has broken (has it not?) - PharmaTimes
2024年8月28日 · A bold new opportunity to address research challenges. So, now we have a new Government, there is a new opportunity to address the challenges we have created for international collaboration in pharmaceutical research.
July/August 2021 - PharmaTimes
Whilst we have seen the COVID pandemic wreak havoc on care pathways across the country, it has also spurred closer and more concentrated working relationships between all factions of healthcare, with the common goal of improving outcomes for patients. And so learnings from this year’s Patient ...
AMR – the fight continues - PharmaTimes
2020年12月15日 · A new wave of innovation is tackling antibiotic resistance. The misuse and overuse of antibiotics has consequences. We are in very real danger of creating an environment where chemotherapy is unsafe, pneumonia becomes untreatable and a simple cut can kill.
PharmaTimes | in-depth news, features and insights for the ...
Subscribe; Advertise; About us; Follow; Follow; Follow; Follow; GO
Drive time - PharmaTimes
2022年3月1日 · If the power of human interaction is removed, or reduced, it will make it harder to build trust around clinical trials. Worries over data privacy also exacerbate this, which means communicating what will happen with patient data – in a clear, approachable way – is paramount.
PharmaTimes - March 2022
I always said that one day pharma would be unmasked, demystified and fully inducted into popular culture. Admittedly, I didn’t realise it would take an international pandemic for this wildly optimistic vision to unfold. Nevertheless, that is the status …
In the real world - PharmaTimes
Differences in population access to healthcare . Virtual hospital visits reached an all-time high during the height of the pandemic. Telehealth visits surged in March 2020 compared to the baseline January and February 2020, while in April, the percentage of telehealth visits peaked, comprising 17% of all medical visits.